Pages
Products
Human CD47 Knockout Cell Line-K562

Human CD47 Knockout Cell Line-K562

Cat.No. :  CSC-RT2758

Host Cell:  K562 Target Gene:  CD47

Size:  1x10^6 cells/vial, 1mL Validation:  Sequencing

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Cat. No. CSC-RT2758
Description This cell is a stable cell line with a homozygous knockout of human CD47 using CRISPR/Cas9.
Target Gene CD47
Host Cell K562
Host Cell Species Homo sapiens (Human)
Size Form 1 vial (>10^6 cell/vial)
Shipping Dry ice package
Storage Liquid Nitrogen
Revival Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media.
Mycoplasma Negative
Format One frozen vial containing millions of cells
Storage Liquid nitrogen
Safety Considerations

The following safety precautions should be observed.

1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum.

2. No eating, drinking or smoking while handling the stable line.

3. Wash hands after handling the stable line and before leaving the lab.

4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells.

5. All waste should be considered hazardous.

6. Dispose of all liquid waste after each experiment and treat with bleach.

Ship Dry ice
Quick Inquiry

Background

Applications

Publications

Q & A

Customer Reviews

CD47, also known as integrin-associated protein (IAP), is a transmembrane protein widely expressed on various cell types in the human body. It plays a crucial role in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. CD47 primarily interacts with its receptor, signal regulatory protein α (SIRPα), which is primarily found on macrophages and dendritic cells. This interaction is a key "don't eat me" signal to the immune system, preventing macrophages from engulfing healthy cells. Many tumor cells overexpress CD47, thereby exploiting the "don't eat me" signal to evade clearance by the immune system. This overexpression is often associated with a poor prognosis in various cancers because it allows malignant cells to proliferate and metastasize without being inhibited by the body's natural defenses. Therefore, CD47 has attracted great interest as a therapeutic target for cancer treatment. Monoclonal antibodies designed to block the interaction between CD47 and SIRPα are currently being studied in clinical trials, with the potential to enhance the body's ability to fight cancer by promoting phagocytosis of tumor cells.
1. Cancer Research: CD47 is known as the "don't eat me" signal that cancer cells use to evade immune surveillance. By knocking out CD47, researchers can study how the loss of this protein affects tumor cell behavior and immune system interactions, thereby exploring new therapeutic strategies to enhance anti-tumor immunity. 2. Immunotherapy Development: CD47 knockout K562 cells play an important role in the development and testing of immunotherapies. These cells can be used to screen drugs and antibodies that target the CD47-SIRPα interaction. 3. Hematopoietic Stem Cell Research: K562 is a leukemic cell line derived from a patient with chronic myeloid leukemia. Studying CD47-deficient K562 cells helps to gain insight into the role of CD47 in hematopoietic stem cell biology and leukemia development. 4. Drug Resistance Research: Analysis of drug resistance mechanisms in CD47 knockout K562 cells can reveal how CD47 leads to resistance to various chemotherapeutic drugs. By understanding these mechanisms, researchers can develop strategies to overcome drug resistance in cancer treatment, thereby improving treatment outcomes and patient survival. 5. Cell Signaling Pathway Studies: The K562 CD47 knockout cell line is also used to dissect cell signaling pathways involved in immune evasion and cellular homeostasis. By comparing signaling pathways in wild-type and CD47 knockout cells, scientists can identify key molecules and interactions affected by the loss of CD47.
Customer Q&As
How is the knockout cell line validated?

A: The knockout cell product is validated by PCR amplification and Sanger Sequencing to confirm the mutation at the genomic level. Please find the detailed mutation info in the datasheet.

Is the product a single clonal cell or mixed cell pool?

A: Single clonal cell.

Can I confirm gene knockout by RT-qPCR?

A: No. This knockout cell product is generated using the CRISPR/Cas9 system to induce small insertions or deletions (indels) resulting in frameshift mutations. Although these frameshift mutations typically disrupt the coding gene, there is a possibility that the non-functional transcript may still be transcribed. Consequently, this could potentially yield misleading results when analyzed by RT-qPCR.

How can I store the cell product?

A: The cell line should be stored in liquid nitrogen for long-term preservation.

Is it possible to get multiple knockout clones for my GOI?

A: For most cases, we often keep at least 2 clones with different frameshift mutations. Please feel free to contact us to check if there are additional available clones.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Simple operation

Once I received the KO cell line product, I only had to follow the manual and no special treatment was required.

Germany

10/09/2021

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction